Prefer to view this content on our website? Click here.
Dear Fellow Investor,
An Insider Just Bought a Million Shares for $25 Million
If insiders are putting their money where their mouths are, there’s a reason for it.
After all, corporate insiders — the CEOs, CFOs, COOs, and directors — have a front-row seat to everything happening inside their company. They know the challenges, the growth plans, and the financial health long before the rest of Wall Street does. So when they start buying large blocks of stock, it’s often a powerful signal that they see brighter days ahead.
And lately, we’ve seen a number of insiders making big moves — even as broader markets remain choppy. These insiders aren’t just talking up their companies; they’re investing millions of their own dollars into them.
Let’s take a closer look at three of the most interesting insider purchases making headlines right now — and why each could point to a potential opportunity for investors.
Company: Kinder Morgan (SYM: KMI)
Energy giant Kinder Morgan (SYM: KMI) recently caught investors’ attention after Executive Chairman Richard Kinder made a massive insider purchase — snapping up one million shares worth just under $26 million on October 27.
When an executive of Kinder’s stature — and with his name literally on the company — makes a purchase that large, investors take notice. It’s a strong show of confidence at a time when the market is recalibrating around shifting energy demand.
Kinder Morgan shares had slipped from about $28.91 to a low of $25.74, but now appear to have found solid support and begun to pivot higher. Technically, the next target is a retest of the $28.91 level, which would represent a roughly 12% rebound from recent lows.
Behind this move is a broader energy transformation tied to one of the decade’s biggest themes: artificial intelligence.
As noted by Reuters and JLL, the surge in AI adoption and the explosive growth of data centers are creating unprecedented electricity demand. JLL reports that consumers and businesses are expected to generate twice as much data in the next five years as was created over the past ten years combined. That data has to live somewhere — and those data centers require massive amounts of natural gas-powered electricity to stay online.
That’s where Kinder Morgan comes in. As one of North America’s largest energy infrastructure companies, it plays a critical role in transporting natural gas — the very fuel that’s powering data centers, homes, and industries across the U.S.
In short, as AI adoption accelerates, energy infrastructure demand follows — and that’s bullish for Kinder Morgan’s future earnings.
Adding to its appeal, KMI offers an attractive 4.5% dividend yield, providing a steady stream of income while investors wait for price appreciation. The company recently announced a dividend of $0.2925 per share, payable on November 17, 2025, to shareholders of record as of November 3. That kind of consistency makes Kinder Morgan not just a play on energy growth, but also a reliable income stock for long-term investors.
Percent Securities
Beyond Stocks: Smart Money Chooses Private Credit
The traditional 60/40 portfolio faces unprecedented headwinds in 2025. BlackRock now recommends up to 19% allocation to alternatives, including private credit - an asset class that's grown 19x since 2006, offering both yield potential and portfolio diversification.
Percent's platform gives accredited investors access to institutional-quality private credit deals starting at $500. Our marketplace has facilitated over $2B in transactions, with average net returns to investors of 14.9% in 2024.
Experience why sophisticated investors are adding private credit to their portfolios. New investors receive up to $500 on their first investment.
Modernize your portfolio strategy
Company: Summit Therapeutics (SYM: SMMT)
Over in the biotech world, Summit Therapeutics (SYM: SMMT) has been quietly attracting attention from its own insiders.
Director Xia Yu recently purchased about $10 million worth of shares on October 21 at an average price of $18.74 each. Not to be outdone, Co-CEO Robert Duggan also bought approximately $500,000 worth of stock around the same time.
Whenever multiple executives are buying at once, it often signals a shared conviction about the company’s prospects. In this case, the insider buying appears to be tied to Summit’s lead drug candidate, ivonescimab, which has been generating buzz in the medical community for its promising clinical results in treating advanced lung cancer.
The company believes ivonescimab could become a multi-billion-dollar drug, given the size of the global lung cancer treatment market and the unmet need for more effective therapies. If the data continues to hold up in future trials, Summit could be sitting on one of the next major breakthroughs in oncology.
At around $18.93 per share, the stock is still trading close to the insiders’ purchase price — suggesting there may be room for upside if momentum continues. And because biotech tends to move on catalysts, any positive clinical updates or partnership announcements could be powerful triggers for the stock.
It’s also worth noting that Robert Duggan has a reputation for spotting opportunity early. He’s best known for his successful run at Pharmacyclics, where he helped lead the company from a small-cap biotech to a multi-billion-dollar acquisition by AbbVie. When someone with that track record is buying again, investors tend to pay attention.
For now, insider sentiment at Summit remains firmly bullish — and that’s a signal worth noting.
Brownstone
“Partner” with Elon Musk on Project Colossus… Before November 1st
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you…
To partner with Elon on what he believes will be the biggest AI project of the century…
Starting with as little as $500.
Click here to see how you could take a stake in Elon’s private company…
Without having connections in Silicon Valley or having to be an accredited investor.
Company: Cassava Sciences (SYM: SAVA)
Few stocks have had a more turbulent run than Cassava Sciences (SYM: SAVA).
Once hailed as a potential leader in Alzheimer’s treatment, the stock fell sharply late last year after the company announced plans to pause its Alzheimer’s drug studies. The market reaction was brutal, with shares collapsing as investors fled the uncertainty.
But recently, the tide may be turning.
In September, President and CEO Remi Barbier made a notable insider purchase — buying 237,941 shares for about $534,743 at prices between $2.13 and $2.29 per share. That’s a meaningful vote of confidence in a company that many had written off.
The stock, while still beaten down, has begun to show early signs of stabilization, and Barbier’s purchase has injected a new dose of optimism into the story. After all, no one knows Cassava’s potential pipeline better than its own CEO.
In a recent statement, Barbier emphasized that the company is now pivoting toward a new research direction focused on TSC-related epilepsy, a rare and serious disease that affects both children and adults.
He noted:
“We have initiated a new program focused on TSC-related epilepsy, a rare disease for which patients urgently need more treatment options. Two encouraging animal model studies — one conducted at Yale and another with the TSC Alliance — support the exploration of simufilam as a novel, first-in-class approach to this disease.”
Following the positive preclinical data, Cassava announced that it plans to begin a clinical study in the first half of 2026 to explore simufilam as a potential treatment for this rare condition.
For investors, this could mark a fresh start for Cassava. While it’s still speculative, the combination of insider buying and a renewed research pipeline could make SAVA a high-risk, high-reward opportunity worth keeping on the radar.
Banyan Hill
President Trump Just Privatized The U.S. Dollar
A controversial new law (S.1582) just gave a small group of private companies legal authority to create a new form of government-authorized money.
In this urgent presentation, world-leading economist Addison Wiggin reveals how to use this new money… why it's set to make early investors' fortunes, and what to do before the wealth transfer begins on November 18 if you want to profit.
Go here for details now — while you still have time to position yourself.
Are there any other stocks with recent insider buying that you've picked up recently? What sectors of the market you think are on their way up right now? Hit "reply" to this email and let us know your thoughts!
